MoneyWorks4Me

Zydus Lifesciences informs about press release

06 Dec 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated December 6, 2023 titled ‘Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1242.00
Cipla 1331.00
Lupin 1953.75
Zydus Lifesciences 1113.00
View more..